Lumos Pharma Statistics

Total Valuation

Lumos Pharma has a market cap or net worth of $35.50 million. The enterprise value is $19.80 million.

Market Cap	35.50M
Enterprise Value	19.80M

Important Dates

The next estimated earnings date is Friday, November 8, 2024, after market close.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Lumos Pharma has 8.12 million shares outstanding. The number of shares has decreased by -2.41% in one year.

Shares Outstanding	8.12M
Shares Change (YoY)	-2.41%
Shares Change (QoQ)	+0.09%
Owned by Insiders (%)	14.80%
Owned by Institutions (%)	29.75%
Float	5.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.24
Forward PS	n/a
PB Ratio	3.52
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	13.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.23, with a Debt / Equity ratio of 0.04.

Current Ratio	4.23
Quick Ratio	3.44
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -132.56% and return on invested capital (ROIC) is -85.92%.

Return on Equity (ROE)	-132.56%
Return on Assets (ROA)	-60.50%
Return on Capital (ROIC)	-85.92%
Revenue Per Employee	$45,030
Profits Per Employee	-$1.08M
Employee Count	33
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.92% in the last 52 weeks. The beta is 0.36, so Lumos Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.36
52-Week Price Change	+15.92%
50-Day Moving Average	3.84
200-Day Moving Average	2.88
Relative Strength Index (RSI)	61.51
Average Volume (20 Days)	97,207

Short Selling Information

The latest short interest is 285,411, so 3.51% of the outstanding shares have been sold short.

Short Interest	285,411
Short Previous Month	300,199
Short % of Shares Out	3.51%
Short % of Float	5.37%
Short Ratio (days to cover)	10.16

Income Statement

In the last 12 months, Lumos Pharma had revenue of $1.49 million and -$35.75 million in losses. Loss per share was -$4.42.

Revenue	1.49M
Gross Profit	1.49M
Operating Income	-37.62M
Pretax Income	-35.75M
Net Income	-35.75M
EBITDA	-37.59M
EBIT	-37.62M
Loss Per Share	-$4.42

Full Income Statement

Balance Sheet

The company has $16.80 million in cash and $449,000 in debt, giving a net cash position of $16.35 million or $2.01 per share.

Cash & Cash Equivalents	16.80M
Total Debt	449,000
Net Cash	16.35M
Net Cash Per Share	$2.01
Equity (Book Value)	10.28M
Book Value Per Share	1.26
Working Capital	15.96M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-34.49M
Capital Expenditures	n/a
Free Cash Flow	-34.49M
FCF Per Share	-$4.25

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-2,531.70%
Pretax Margin	-2,405.72%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-2,320.79%

Dividends & Yields

Lumos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.41%
Shareholder Yield	2.41%
Earnings Yield	-98.89%
FCF Yield	-95.39%

Analyst Forecast

The average price target for Lumos Pharma is $9.38, which is 114.65% higher than the current price. The consensus rating is "Buy".

Price Target	$9.38
Price Target Difference	114.65%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	142.21%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Lumos Pharma has an Altman Z-Score of -15.31 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.31
Piotroski F-Score	2